301087 Cofoe Medical Technology
WatchlistCofoe Medical Technology News
Kefu Healthcare (301087. SZ): Repurchased 2.01% of shares at a total cost of 156 million yuan
Gelonghui (301087.SZ) announced on December 1 | Kefu Healthcare (301087.SZ) announced that as of November 30, 2023, the company has repurchased 4202369 million shares of the company's shares through centralized bidding transactions through special repurchase securities accounts, accounting for 2.01% of the company's total share capital of 209,238,250 shares. The highest transaction price is 39.77 yuan/share, the lowest transaction price is 36.00 yuan/share, and the total transaction amount is 156 million yuan (excluding transaction fees).
Kefu Healthcare (301087): 23Q3 revenue structure optimization, gross margin continues to rise
The incident company released its 2023 three-quarter report. The first three quarters of 2023 achieved operating income of 2.124 billion yuan, an increase of 13.11% over the previous year; realized net profit of 242 million yuan, an increase of 44.47% over the previous year; achieved
Zhang Shaoda, the core technician of Kefu Medical (301087.SZ), resigned and added the certification of Quan Changyun as the core technician
Kefu Medical (301087.SZ) announced that Zhang Shaoda, the company's core technician, resigned from the relevant position due to personal reasons,...
Kefu Healthcare (301087. SZ): Repurchased 2.00% of shares at a cumulative cost of about 156 million yuan
Glonghui on October 31 | Kefu Healthcare (301087.SZ) announced that as of October 31, 2023, the company has repurchased a total of 4184769 million shares of the company's shares through centralized bidding transactions through special securities repurchase accounts, accounting for an increase in the company's total share capital (due to the increase in share capital due to the company's 2021 restricted stock incentive plan, the total number of shares of the company increased from 208,487,500 shares to 209,238,250 shares), with a maximum transaction price of 39.12 yuan/share , the lowest transaction price is 36.
About 1,396,500 restricted shares of Kefu Healthcare (301087.SZ) will be listed and distributed on October 25
Kefu Healthcare (301087.SZ) announced that the number of shareholders applying for the lifting of share sales restrictions this time is 1 (Western...
Kefu Healthcare (301087.SZ): Revenue from rehabilitation aids products increased by 22.54% year-on-year in the first half of the year
Glonghui, October 19丨Kefu Medical (301087.SZ) stated on the investor interaction platform that the company's manual wheelchairs and electric wheelchairs are classified as rehabilitation aids. In the first half of this year, the company's revenue from rehabilitation aids products increased by 22.54% year-on-year. Among them, the sales volume of wheelchair products increased well.
The repurchase ratio of Kefu Medical (301087.SZ) reached 1.89% and cost 146 million yuan
Kefu Healthcare (301087.SZ) announced that up to now, the company has repurchased a total of 3.942,900 shares, accounting for...
Kefu Healthcare (301087): Product Upgrades, Self-Production+Hearing Expansion, and Store Card Slots Drive the Company's Healthy Growth
A leading household medical device company, is in a period of rapid growth. It has been covered for the first time. It has been covered for the first time. Granted a “buy” rating, Kefu Medical has focused on household medical devices for 14 years. After years of deepening channel cultivation and R&D and product expansion, it has formed health monitoring, rehabilitation aids, and respiratory support
Kefu Healthcare (301087): Performance growth is resilient enough to be optimistic about steady growth throughout the year
Event Overview On August 29, 2023, the company released its 2023 interim report. In the first half of 2023, it achieved revenue of 1,519 billion yuan, an increase of 17.23% over the previous year; it achieved net profit of 199 million yuan, a year-on-year increase of 52 million yuan.
Kefu Healthcare (301087.SZ): By the end of August, nearly 700 hearing testing centers had been signed and nearly 600 had been opened
Glonghui September 4 丨 Kefu Healthcare (301087.SZ) recently received a survey of specific subjects on “Long-term plans and future positioning of the Jianer store?” The company replied that by the end of August, nearly 700 hearing testing and matching centers had been signed and nearly 600 had been opened. It will continue to expand at a high rate in the next 1-2 years, and strive to become the leading hearing service chain brand in China. Currently, the concentration of the hearing industry is low. Through continuous improvement of coverage and professional service capabilities, Jianear Hearing hopes to better serve consumers. At the same time, through the development of hearing testing equipment and products, the company's competitiveness will be enhanced and the cost of opening a store will be reduced.
Kefu Healthcare (301087.SZ): The respiratory support sector has a small revenue base and will achieve relatively rapid growth in the second half of this year
GLONGHUI, September 4丨Kefu Healthcare (301087.SZ) recently accepted a survey of specific subjects on “What are the profit expectations for respiratory support products?” The company replied that respiratory support is one of the categories the company is focusing on this year. In the past, the self-production ratio of products in this sector was low. The company mainly outsourced through agents and private brands, and the overall market share was low. Since the end of last year, the company has independently developed and produced products such as oxygen concentrators and nasal sprays. This year, it also launched a number of new products, boosting the growth of brand value and sales scale. As public awareness of health continues to increase, ventilators, oxygen concentrators, nebulizers, and nasal care
Kefu Healthcare (301087.SZ): In the first half of the year, it achieved revenue of 782 million yuan from self-produced products, accounting for 53.63% of main business revenue
Glonghui September 4 丨 Kefu Medical (301087.SZ) recently received a survey from a specific target, saying, “What is the current self-production ratio of products? The mid-term report that rehabilitation assistance is growing rapidly. Does the source of growth in the second half of the year depend on this?” The company replied that during the reporting period, the company achieved revenue of 782 million yuan from self-produced products, an increase of 31.17% over the previous year, accounting for 53.63% of main business revenue. The company has progressed in an orderly manner the adjustment of the production capacity structure of the two production bases in Changsha and Xiangyin and the commissioning of new products, continuously optimized the product structure, and enhanced product quality and cost advantages. In the first half of the year, income from rehabilitation aids increased
Kefu Healthcare (301087.SZ): It spent a total of about 136 million yuan to repurchase 1.77% of the shares
Glonghui, September 4, 丨Kefu Medical (301087.SZ) announced that as of August 31, 2023, the company has repurchased a total of 3,680,769 shares of the company through centralized bidding transactions through a special securities repurchase account, accounting for 1.77% of the company's current total share capital. The highest transaction price is 37.94 yuan/share, the lowest transaction price is 36.00 yuan/share, and the total transaction amount is about 136 million yuan (excluding transaction fees).
Kefu Healthcare (301087): Respiratory support classes are growing at a significant rate, strengthening ears, and speeding up the expansion of hearing
Incident Company released the 2023 semi-annual report. In the first half of 2023, the company achieved operating income of 1,519 billion yuan, an increase of 17% over the previous year; realized net profit of 199 million yuan, an increase of 53% over the previous year; achieved non-return deduction
Kefu Medical (301087.SZ) and its subsidiaries obtained 2 medical device registration certificates
Kefu Medical (301087.SZ) announced that the company and its subsidiaries recently received an issue from the Hunan Drug Administration...
Kefu Healthcare (301087.SZ) released first-half results, net profit of 199 million yuan, an increase of 52.73%
Kefu Healthcare (301087.SZ) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Kefu Healthcare (301087): Online channel sales are growing rapidly, and the layout of hearing health is accelerating
Brief performance description On August 29, 2023, the company released its semi-annual report for 2023. In the first half of 2023, the company achieved revenue of 1,519 million yuan, +17% year-on-year; realized net profit of 199 million yuan.
Kefu Healthcare (301087.SZ): The share repurchase amount within the next 90 days is not less than 20 million yuan
Kefu Healthcare (301087.SZ) announced that the company will actively promote work related to share repurchases. It is expected that in the future...
Kefu Healthcare (301087.SZ): A cumulative cost of 136 million yuan to repurchase 1.77% of shares
GLONGHUI, August 1, 丨Kefu Healthcare (301087.SZ) announced that as of July 31, 2023, the company has purchased a total of 3,680,769 shares of the company's shares through centralized bidding transactions through the repurchase of dedicated securities accounts, accounting for 1.77% of the company's current total share capital. The highest transaction price is 37.94 yuan/share, the minimum transaction price is 36.00 yuan/share, and the total transaction amount is 136 million yuan (excluding transaction fees).
Kefu Healthcare (301087.SZ) products pass the special examination procedure for innovative medical devices and obtain a medical device registration certificate
According to the Zhitong Finance App, Kefu Medical (301087.SZ) announced that the company recently received a copy of the “Hunan Province Class II Innovative Medical Device Special Examination Results Notice” (ID: Xiangji Innovation 2023010), 1 “Medical Device Registration Certificate”, and 1 “Medical Device Change Registration (Filing) Document” issued by the Hunan Drug Administration. According to reports, the name of the product that passed the special examination of innovative medical devices is a blood glucosuric acid test strip; the name of the product that obtained the medical device registration certificate is a blood glucose meter. This product is used in conjunction with the accompanying blood sugar test strip to monitor human capillary whole blood in vitro,